AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.
AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 150.00% and 8.01%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
by Zacks Equity Research
The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.
HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.
AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat
by Zacks Equity Research
AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.
Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.
Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.
Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.
Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.
LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.
Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3
by Zacks Equity Research
Inogen (INGN) saw revenue decline within its Sales segment in Q3
PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) rides high on the launch of the Axeos imaging system in the third quarter.
Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume
Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.
Change Healthcare (CHNG) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance in the Network Solutions segment.
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.